Mucosal immune system enhancement

Mucosal immune system enhancement refers to the physiological process of strengthening immune defenses at mucosal surfaces, such as the gastrointestinal, respiratory, and urogenital tracts, to prevent pathogen entry and maintain homeostasis (Mowat & Agace, 2014, Science). It is not a single molecular target, such as a receptor or enzyme, but rather a complex biological outcome involving the activation of Mucosa-Associated Lymphoid Tissue (MALT) and the production of secretory IgA (sIgA) (Neutra & Kozlowski, 2006, Nature Reviews Immunology). Therapeutic strategies aiming for mucosal enhancement often utilize mucosal vaccines, adjuvants like Cholera toxin B subunit, or probiotics to stimulate localized immune responses (Kiyono & Azegami, 2015, NIH). This approach is particularly relevant for infectious diseases, where localized immunity can provide a first line of defense that systemic immunity might miss. However, the challenge in drug development lies in achieving potent activation without triggering chronic inflammation, autoimmunity, or the induction of oral tolerance, which can negate the intended protective effect. Consequently, while 'mucosal immune system enhancement' describes a therapeutic goal, drug discovery efforts focus on specific molecular triggers within the mucosal environment to achieve this state.

Other names

Mucosal immunity stimulationEnhancement of mucosal defensesMucosal immune response inductionBoosting mucosal immunity

Activation of mucosa-associated lymphoid tissue (MALT) and induction of secretory IgA (sIgA) production.